These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18615102)

  • 1. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia.
    Tyner JW; Loriaux MM; Erickson H; Eide CA; Deininger J; MacPartlin M; Willis SG; Lange T; Druker BJ; Kovacsovics T; Maziarz R; Gattermann N; Deininger MW
    Leukemia; 2009 Feb; 23(2):406-9. PubMed ID: 18615102
    [No Abstract]   [Full Text] [Related]  

  • 2. High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations.
    Vivante A; Amariglio N; Koren-Michowitz M; Ashur-Fabian O; Nagler A; Rechavi G; Cohen Y
    Leukemia; 2007 Jun; 21(6):1318-21. PubMed ID: 17330094
    [No Abstract]   [Full Text] [Related]  

  • 3. High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.
    Poláková KM; Lopotová T; Klamová H; Moravcová J
    Leuk Res; 2008 Aug; 32(8):1236-43. PubMed ID: 18308387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia.
    Tono C; Xu G; Toki T; Takahashi Y; Sasaki S; Terui K; Ito E
    Leukemia; 2005 Oct; 19(10):1843-4. PubMed ID: 16079889
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutational analysis in chronic myeloid leukemia: when and what to do?
    Branford S; Hughes TP
    Curr Opin Hematol; 2011 Mar; 18(2):111-6. PubMed ID: 21245758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
    Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M
    Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
    Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ
    Rev Invest Clin; 2004; 56(5):605-8. PubMed ID: 15776864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not just another kinase. New knowledge about myeloproliferative disease].
    Bjerrum OW
    Ugeskr Laeger; 2006 Sep; 168(39):3293. PubMed ID: 17032590
    [No Abstract]   [Full Text] [Related]  

  • 12. [c-abl gene and bcr-abl fused gene in Ph1-positive leukemias].
    Okabe M; Kunieda Y; Miyazaki T; Kakinuma M
    Nihon Rinsho; 1990 Aug; 48(8):89-97. PubMed ID: 2255098
    [No Abstract]   [Full Text] [Related]  

  • 13. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying the pathogenesis of BCR-ABL+ leukemia in mice.
    Van Etten RA
    Oncogene; 2002 Dec; 21(56):8643-51. PubMed ID: 12476310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
    Skórski T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
    Melo JV; Myint H; Galton DA; Goldman JM
    Leukemia; 1994 Jan; 8(1):208-11. PubMed ID: 8289491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
    Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring treatment of chronic myeloid leukemia.
    Baccarani M; Pane F; Saglio G
    Haematologica; 2008 Feb; 93(2):161-9. PubMed ID: 18245647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.